Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes. / Andersen, Marie; Ruhwald, Morten; Thorn, Mette; Pedersen, Anders; Mathiassen, Susanne; Buus, Soren; Claesson, Mogens.

I: Journal of Immune Based Therapies and Vaccines, Bind 1, Nr. 1, 2003, s. 1.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Andersen, M, Ruhwald, M, Thorn, M, Pedersen, A, Mathiassen, S, Buus, S & Claesson, M 2003, 'Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes.', Journal of Immune Based Therapies and Vaccines, bind 1, nr. 1, s. 1.

APA

Andersen, M., Ruhwald, M., Thorn, M., Pedersen, A., Mathiassen, S., Buus, S., & Claesson, M. (2003). Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes. Journal of Immune Based Therapies and Vaccines, 1(1), 1.

Vancouver

Andersen M, Ruhwald M, Thorn M, Pedersen A, Mathiassen S, Buus S o.a. Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes. Journal of Immune Based Therapies and Vaccines. 2003;1(1):1.

Author

Andersen, Marie ; Ruhwald, Morten ; Thorn, Mette ; Pedersen, Anders ; Mathiassen, Susanne ; Buus, Soren ; Claesson, Mogens. / Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes. I: Journal of Immune Based Therapies and Vaccines. 2003 ; Bind 1, Nr. 1. s. 1.

Bibtex

@article{db7ed800ac0511ddb5e9000ea68e967b,
title = "Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes.",
abstract = "Thirteen H-2b-binding peptides derived from six potentially overexpressed proteins in p53-/- thymoma (SM7) cells were studied for immunogenecity and vaccine-induced prevention of tumor growth in mice inoculated with SM7 tumor cells. Six of the peptides generated specific CTL responses after immunization, but only two of these peptides (RAD23-31 and RAD24-31) were capable of generating a weak vaccination-induced protection against adoptive tumor growth. SM7 inoculated mice treated with a blocking antibody against the inhibitory T cell signal transducing molecule CTLA4 appeared to delay tumor take, suggesting that SM7 thymoma cells are recognized by the adaptive immune system of the host. However, prophylactic vaccination with RAD23-31 and RAD24-31 peptides combined with anti-CTLA4 Ab treatment and did not improve tumor resistance. Our data would indicate that vaccination with immunogenic peptides derived from potentially overexpressed tumor proteins, as identified by mRNA expression profiling of p53-/- thymoma cells, at best results in a weak tumor protection thus questioning this way of detection of new tumor rejection epitopes.",
author = "Marie Andersen and Morten Ruhwald and Mette Thorn and Anders Pedersen and Susanne Mathiassen and Soren Buus and Mogens Claesson",
year = "2003",
language = "English",
volume = "1",
pages = "1",
journal = "Journal of Immune Based Therapies and Vaccines",
issn = "1476-8518",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes.

AU - Andersen, Marie

AU - Ruhwald, Morten

AU - Thorn, Mette

AU - Pedersen, Anders

AU - Mathiassen, Susanne

AU - Buus, Soren

AU - Claesson, Mogens

PY - 2003

Y1 - 2003

N2 - Thirteen H-2b-binding peptides derived from six potentially overexpressed proteins in p53-/- thymoma (SM7) cells were studied for immunogenecity and vaccine-induced prevention of tumor growth in mice inoculated with SM7 tumor cells. Six of the peptides generated specific CTL responses after immunization, but only two of these peptides (RAD23-31 and RAD24-31) were capable of generating a weak vaccination-induced protection against adoptive tumor growth. SM7 inoculated mice treated with a blocking antibody against the inhibitory T cell signal transducing molecule CTLA4 appeared to delay tumor take, suggesting that SM7 thymoma cells are recognized by the adaptive immune system of the host. However, prophylactic vaccination with RAD23-31 and RAD24-31 peptides combined with anti-CTLA4 Ab treatment and did not improve tumor resistance. Our data would indicate that vaccination with immunogenic peptides derived from potentially overexpressed tumor proteins, as identified by mRNA expression profiling of p53-/- thymoma cells, at best results in a weak tumor protection thus questioning this way of detection of new tumor rejection epitopes.

AB - Thirteen H-2b-binding peptides derived from six potentially overexpressed proteins in p53-/- thymoma (SM7) cells were studied for immunogenecity and vaccine-induced prevention of tumor growth in mice inoculated with SM7 tumor cells. Six of the peptides generated specific CTL responses after immunization, but only two of these peptides (RAD23-31 and RAD24-31) were capable of generating a weak vaccination-induced protection against adoptive tumor growth. SM7 inoculated mice treated with a blocking antibody against the inhibitory T cell signal transducing molecule CTLA4 appeared to delay tumor take, suggesting that SM7 thymoma cells are recognized by the adaptive immune system of the host. However, prophylactic vaccination with RAD23-31 and RAD24-31 peptides combined with anti-CTLA4 Ab treatment and did not improve tumor resistance. Our data would indicate that vaccination with immunogenic peptides derived from potentially overexpressed tumor proteins, as identified by mRNA expression profiling of p53-/- thymoma cells, at best results in a weak tumor protection thus questioning this way of detection of new tumor rejection epitopes.

M3 - Journal article

C2 - 12709261

VL - 1

SP - 1

JO - Journal of Immune Based Therapies and Vaccines

JF - Journal of Immune Based Therapies and Vaccines

SN - 1476-8518

IS - 1

ER -

ID: 8443116